|
|
||||||||
Part 2: Cellular and Molecular Biology of the Peritoneum and Peritoneal Dialysis |
Dialysis Unit,1 Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Instituto Reina Sofía de Investigación Nefrológica; Servicio de Nefrología,2 Hospital Universitario La Paz; Laboratory of Cellular Biology in Renal Diseases,3 Universidad Autónoma de Madrid, Madrid, Spain
a All authors (except JE) belong to REDinREN (Red de Investigación Renal Española del Instituto de Salud Carlos III, RETICS 06/0016).
Correspondence to: A. Ortiz, Unidad de Diálisis, Fundación Jiménez Díaz, Av Reyes Católicos 2, 28040 Madrid, Spain. aortiz{at}fjd.es
Excessive, insufficient, or untimely apoptosis may result in disorders
of cell numbers. Peritoneal demesothelization is an example of disease by
decreased cell number; untimely leukocyte apoptosis impairs peritoneal
defense. Conventional peritoneal dialysis solutions accelerate neutrophil
apoptosis. Glucose degradation products such as 3,4-dideoxyglucosone-3-ene
(3,4-DGE) decisively contribute to apoptosis induced by these solutions, in
both leukocytes and mesothelial cells and in both culture and peritoneal
dialysis patients. Pan-caspase inhibition retards neutrophil apoptosis and
improves peritoneal clearance of Staphylococcus aureus in animal
models. However, regulation of apoptosis in mesothelial cells is more complex
than in leukocytes, and caspase inhibitors may not be the optimal drugs to
modulate apoptosis in these cells. In this regard, Bax antagonistic peptides
protect mesothelial cells from 3,4-DGE. In addition, novel molecular targets
have been identified. Short-term modulation of apoptosis may be useful to
accelerate recovery and to prevent irreversible peritoneal injury following
peritonitis.
KEY WORDS: Apoptosis; caspases; Bax; Bcl-xL; mesothelial; peritonitis.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |